KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Current Assets: 2012-2025

Historic Current Assets for Travere Therapeutics (TVTX) over the last 13 years, with Sep 2025 value amounting to $371.1 million.

  • Travere Therapeutics' Current Assets rose 14.28% to $371.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $371.1 million, marking a year-over-year increase of 14.28%. This contributed to the annual value of $416.7 million for FY2024, which is 32.44% down from last year.
  • According to the latest figures from Q3 2025, Travere Therapeutics' Current Assets is $371.1 million, which was down 2.23% from $379.6 million recorded in Q2 2025.
  • Travere Therapeutics' Current Assets' 5-year high stood at $686.2 million during Q3 2023, with a 5-year trough of $324.7 million in Q3 2024.
  • Moreover, its 3-year median value for Current Assets was $416.7 million (2024), whereas its average is $469.7 million.
  • In the last 5 years, Travere Therapeutics' Current Assets skyrocketed by 42.01% in 2021 and then slumped by 52.68% in 2024.
  • Travere Therapeutics' Current Assets (Quarterly) stood at $582.8 million in 2021, then decreased by 16.54% to $486.4 million in 2022, then increased by 26.79% to $616.8 million in 2023, then plummeted by 32.44% to $416.7 million in 2024, then climbed by 14.28% to $371.1 million in 2025.
  • Its last three reported values are $371.1 million in Q3 2025, $379.6 million for Q2 2025, and $374.2 million during Q1 2025.